Published On: Mon, May 24th, 2021

Natco Pharma gets FDA approval for Lenalidomide Capsules

Tagged with: | | | | | | | | | | |

Natco Pharma has secured the final approval from the US Food and Drug Administration (FDA) of its abbreviated new drug application (ANDA) for Lenalidomide Capsules, 5mg, 1 Omg, 15mg, and 25mg, and the tentative approval of the 2.5mg and 20mg.

Lenalidomide Capsules is the generic for Bristol-Myers Squibb’s REVLIMID, which is indicated in the US for the of multiple myeloma and .

The Indian pharma company and its marketing partner Arrow International, a US affiliate of had previously settled a litigation pertaining to the product with Celgene, which was acquired by Bristol-Myers Squibb.

Natco Pharma gets FDA approval for Lenalidomide Capsules

Natco Pharma gets FDA approval for Lenalidomide Capsules. Photo courtesy of The U.S. Food and Drug Administration/Wikipedia.org.

Natco Pharma and Arrow International plan to roll out Lenalidomide Capsules on agreed-upon launch dates in the future.

Related posts

Leave a comment

XHTML: You can use these html tags: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>

Recent Posts